Identification of a SART-1-derived peptide capable of inducing HLA-A24- restricted and tumor-specific cytotoxic T lymphocytes

International Journal of Cancer

Volumn 81, Issue 3, 1999, Pages 459-466

  Kikuchi, Megumi ^a   Nakao, Masanobu ^a   Inoue, Yoshiko ^a   Matsunaga, Kazuko ^a   Shichijo, Shigeki ^a   Yamana, Hideaki ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER PATIENT; CRYOPRESERVATION; CYTOTOXIC T LYMPHOCYTE; ESOPHAGUS CANCER; GENE EXPRESSION; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TUMOR CELL CULTURE;

EID: 0032916218     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990505)81:3<459::AID-IJC21>3.0.CO;2-6     Document Type: Article

References (27)

1. BENIT, P., CHANET, R., FABRE, F., FAYE, G., FUKUHARA, H. and SOR, F., Sequence of sup61-RAD18 region on chromosome III of Saccharomyces cerevisiae. Yeast, 8, 147-153 (1992).
2. CELIS, E., FIKES, J., WENTWORTH, P., SIDNEY, J., SOUTHWOOD, S., MAEWAL, A., GUERCIO, M.F.D., SETTE, A. and LIVINGTON, B., Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol. Immunol., 31, 1423-1430 (1994).
3. IBE, M., MOORE, Y.I., MIWA, K., KANEKO, Y., YOKOTA, S. and TAKIGUCHI, M., Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A2402 molecules. Immunogenetics, 44, 233-241 (1996).
4. IKEDA, H., LETHE, B., LEHMANN, F., BAREN, N.V., BAURAIN, J.F., DE SMET, C., CHAMBOST, H., VITALE, M., MORETTA, A., BOON, T. and COULIE, P.G., Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity, 6, 199-208 (1997).
5. IMANISHI, T., AKAZA, T., KIMURA, A., TOKUNAGA, K. and GOJOBORI, T., Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: K. Tsuji, M. Aizawa and T. Sasazuki (eds.), HLA 1991, Vol. 1, pp. 1065-1220, Oxford Scientific Publications, Oxford (1992).
6. KANG, X., KAWAKAMI, Y., EL-GAMIL, M., WANG, R., SAKAGUCHI, K., YANNELI, E., APPELLA, E., ROSENBERG, S.A. and ROBBINS, P.F., Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J. Immunol., 155, 1343-1348 (1995).
7. KAWAKAMI, Y., ELIYAKU, S., SAKAGUCHI, K., ROBBINS, P.F., RIVOLTINI, L., YANNELLI, J.R., APPELLA, E. and ROSENBERG, S.A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognised by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. exp. Med., 180, 347-352 (1994).
8. LOFTUS, D.J., CASTELLI, C., CLAY, T.M., SQUARCINA, P., MARINCOLA, F.M., NISHIMURA, M.I., PARMIANI, G., APPELLA, E. and RIVOLTINI, L., Identification of epitope mimics recognized by CTL reactive to the melanoma/ melanocyte-derived peptide MART-1(27-35). J. exp. Med., 184, 647-657 (1996).
9. MANDRUZZATO, S., BRASSEUR, F., ANDRY, G., BOON, T. and VAN DER BRUGGEN, P.A., CASP-8 mutation recognized by cytolytic lymphocytes on a human head and neck carcinoma. J. exp. Med., 186, 785-793 (1997).
10. MARCHAND, M. and 20 OTHERS, Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63, 883-885 (1995).
11. NAKAO, M., YAMANA, H., IMAI, Y., TOH, Y., TOH, U., KIMURA, A., YANOMA, S., KAKEGAWA, T. and ITOH, K., HLA-A2601-restricted CTLs recognized a peptide antigen expressed on squamous cell carcinoma. Cancer Res., 55, 4248-4252 (1995).
12. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G. and SCHADENDORF, D., Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature (Med.), 4, 328-332 (1998).
13. RAMMENSEE, H.G., FRIEDE, T. and STEVANOVIC, S., MHC ligands and peptide motifs: first listing. Immunogenetics, 41, 178-228 (1995).
14. RIVOLTINI, L., KAWAKAMI, Y., SAKAGUCHI, K., SOUTHWOOD, S., SETTE, A., ROBBINS, P.F., MARINCOLA, F.M., SALGALLER, M.L., YANNELI, J.R. and APPELLA, E., Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154, 2257-2265 (1995).
15. ROBBINS, P.F., EL-GAMIL, M., LI, Y.F., TOPALIAN, S.L., RIVOLTINI, L., SAKAGUCHI, K., APPELLA, E. and ROSENBERG, S.A., Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol., 154, 5944-5950 (1995).
16. ROMANI, L., The T cell response against fungal infections. Curr. Opin. Immunol., 9, 484-490 (1997).
17. ROSENBERG, S.A. and 15 OTHERS, Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature (Med.), 4, 321-328 (1998).
18. SHICHIJO, S., NAKAO, M., IMAI, Y., TAKASU, H., KAWAMOTO, M., NIIYA, P. YANG, D., TOH, Y., YAMANA, H. and ITOH, K., A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. exp. Med., 187, 277-288 (1998).
19. STEVENS, E.J., JACKNIN, L., ROBBINS, P.F., KAWAKAMI, Y., EL-GAMIL, M., ROSENBERG, S.A. and YANNELLI, J.R., Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogenic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J. Immunol., 154, 762-771 (1995).
20. SUGITA, S., SAGAWA, K., MOCHIZUKI, M., SHICHIJO, S. and ITOH, K., Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int. Immunol., 8, 799-803 (1996).
21. TANAKA, F., FUJIE, T., TAHARA, K., MORI, M., TAKESAKO, K., SETTE, A., CELIS, E. and AKIYOSHI, T., Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res., 57, 4465-4468 (1997).
22. TASWELL, C., Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol., 126, 1614-1619 (1981).
23. TOKUNAGA, K. and 13 OTHERS, Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics, 46, 199-205 (1997).
24. TRAVERSARI, C., VAN DER BRUGGEN, P., LUESCHER, I.F., LURQUIN, C., CHOMEZ, P., VAN PEL, A., DE PLAEN, E., AMAR-COSTESEC, A. and BOON, T., A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. exp. Med., 176, 1453-1475 (1992).
25. VALITUTTI, S., MULLER, S., DESSING, M. and LANZAVECCHIA, A., Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. exp. Med., 183, 1917-1921 (1996).
26. VAN DER BRUGGEN, P., BASTIN, J., GAJEWSKI, T., COULIE, P.G., BOEL, P., DE SMET, C., TRAVERSARI, C., TOWNSEND, A. and BOON, T., A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Europ. J. Immunol., 24, 3038-3043 (1994).
27. VERGELLI, A., HEMMER, B., KALBUS, M., VOGT, A.B., LING, N., CONLON, P., COLIGAN, J.E., MCFARLAND, H. and MARTIN, M., Modification of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. J. Immunol., 158, 3736-3752 (1996).